Adropin is a liver-secreted peptide that is crucial for metabolic health. However, the molecular functions and clinical significance of adropin have not been adequately explored. Butler et al. now investigate adropin expression profiles and links to cardiometabolic disease risk in two nonhuman primate models, increasing our translational and mechanistic understanding of this fascinating hormone.
Adropin is a liver-secreted peptide that is crucial for metabolic health. However, the molecular functions and clinical significance of adropin have not been adequately explored. Butler et al. now investigate adropin expression profiles and links to cardiometabolic disease risk in two nonhuman primate models, increasing our translational and mechanistic understanding of this fascinating hormone.
Inter-organ cross-talk is a burning topic in systemic metabolism, fueled by searches for the biomolecules and molecular mechanisms responsible for coordinating organismal health. Hitting the right messenger holds the promise of curing obesity-related cardiometabolic diseases, bypassing dieting cycles. Are we getting anywhere close to this goal? Possibly. Various clinical successes like the peptidic constructs targeting glucagon-like peptide 1 receptor to control insulin secretion and treat diabetes and its complications provide stellar examples. However, many molecules that shine in mouse studies fail in clinical trials. Mice and humans share similar but distinct physiology, so integrating information from animal models such as nonhuman primates can help to convert basic research to successful translational projects. In this issue, Butler and colleagues (1) use two such models to explore the regulation and clinical correlates of adropin, a liver-secreted hormone regulating systemic metabolism whose name is derived from Latin roots aduro (to set fire to) and pinquis (oils) (2) . The authors showed in a longitudinal study of rhesus monkeys that declining levels of adropin predict cardiometabolic risk. These findings provide key pieces of evidence to support the translational value of adropin in promoting metabolic health.
Adropin is a 43-amino acid peptide expressed by the gene ENHO (energy homeostasis-associated). Adropin levels are modulated by macronutrient intake, obesity, and the circadian clock (2, 3); circulating adropin levels rise with feeding and decline with fasting or obesity. Elevated adropin levels in circulation protect against conditions of diet-induced metabolic syndrome such as obesity, glucose intolerance, insulin resistance, and fatty liver (2) . Importantly, the benefits on prediabetes and fatty liver conferred by adropin are not reliant on changes in body weight (4) . Mechanistically, adropin promotes fatty acid utilization over glucose utilization in skeletal muscle (4, 5) . These results have given us first insights into the possible functions of adropin but were primarily explored in mouse models or human association studies. There is one study showing that circulating adropin declines with obesity in nonhuman primates (6), but it is not otherwise known whether adropin biology can be translated from rodents to primates, and particularly humans.
To fill this gap, Butler and colleagues (1) set out to data mine the expression profile of ENHO in baboon tissues. They utilized a recently published database to probe tissue-specific and diurnal patterns of ENHO gene expression in baboons. It is known that ENHO is expressed in the brain and liver in mice. Whereas this is true in baboon tissues, surprisingly, brain regions involved in metabolic regulation, such as amygdala, ventromedial hypothalamus, and lateral hypothalamus, express the highest levels of ENHO. The authors further showed that genes involved in glucose metabolism are positively correlated with the ENHO level, whereas genes involved in lipid/lipoprotein metabolism are negatively correlated. In support of the previously reported circadian regulation of hepatic/circulating adropin, most brain regions and peripheral organs exhibit a diurnal profile of ENHO transcripts. This study demonstrates that the expression profile of ENHO in baboons is consistent with those in mice and humans.
Next, Butler and colleagues (1) explored the association of circulating adropin with cardiometabolic biomarkers in a rhesus monkey model of metabolic syndrome. Rhesus monkeys were fed for 3 months with a high-fructose beverage diet, which rapidly induces weight gain, hyperinsulinemia, and dyslipidemia. Plasma was sampled at baseline and after 1 and 3 months of the diet. Simple modeling of the data revealed a negative correlation between levels of adropin and those of leptin, glucose, ApoA1 (a major high-density lipoprotein (HDL) 2 apoprotein), and ApoC3 (a key component of triglyceride-rich lipoproteins), but a positive correlation between plasma adropin and HDL-C (Fig. 1 ). All diabetic monkeys exhibit a low plasma adropin level. The authors then performed multiple linear regression analysis to find correlates of plasma adropin based on age, body weight, and measures of insulin resistance and dyslipidemia. The results showed that plasma adropin is strongly correlated with measures of adiposity (e.g. plasma leptin) and lipoprotein metabolism (e.g. HDL-C, ApoA1, and ApoC3). Grouping of the monkeys based on plasma adropin levels produced similar results. This shows that a low level of adropin in circulation signals the risks of cardiometabolic diseases in a nonhuman primate model of metabolic syndrome. In this paper, the in silico analysis of the average and diurnal expression profile of ENHO in baboon tissues lays out a strong foundation that the adropin precursor gene ENHO shares similar regulatory mechanisms from mice to humans and prompts several new questions. First, what is the function of adropin in the central nervous system, especially in the context of obesity? Second, what is the source of circulating adropin? The presence of ENHO in neurons is evident in different unbiased tissue transcript profiling from mice, baboons, and humans. Now it is time to tackle these questions via tissue-specific gene targeting.
Given the strong association between plasma adropin and dyslipidemia in the obese monkey cohort, adropin may be a valuable target to address the unmet clinical needs for curbing dyslipidemia on top of statins. Basic research is therefore encouraged to identify the adropin receptor and its downstream signaling program in metabolic organs. Recently, Stein et al. (7) reported that the adropin receptor may be a G proteincoupled receptor from the cell surface. It would be particularly interesting to test whether adropin's signaling pathways converge with those of plasma fatty acid-binding protein 4, a well-established biomarker and hormone coupling obesity to obesity-associated pathologies (8, 9) . In either case, the new information from Butler and colleagues' studies (1) might inform adropin-based therapies to control cardiometabolic disease in the nonhuman primate model, and perhaps in humans in the future. EDITORS' PICK HIGHLIGHT: Setting fire to fat
